[go: up one dir, main page]

SG11201901137UA - Silk-derived protein for treating inflammation - Google Patents

Silk-derived protein for treating inflammation

Info

Publication number
SG11201901137UA
SG11201901137UA SG11201901137UA SG11201901137UA SG11201901137UA SG 11201901137U A SG11201901137U A SG 11201901137UA SG 11201901137U A SG11201901137U A SG 11201901137UA SG 11201901137U A SG11201901137U A SG 11201901137UA SG 11201901137U A SG11201901137U A SG 11201901137UA
Authority
SG
Singapore
Prior art keywords
international
silk
sdp
minnesota
rule
Prior art date
Application number
SG11201901137UA
Inventor
Brian D Lawrence
David W Infanger
Original Assignee
Silk Technologies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Silk Technologies Ltd filed Critical Silk Technologies Ltd
Publication of SG11201901137UA publication Critical patent/SG11201901137UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43586—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from silkworms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/14—Eye parts, e.g. lenses or corneal implants; Artificial eyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Insects & Arthropods (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property --11` . 1#11101111 0 11101 HOE 3E1 0 0111E011H MO Ell 0011110 1111 OEN Organization International Bureau (10) International Publication Number (43) International Publication Date ..../.- WO 2018/031973 Al 15 February 2018 (15.02.2018) WIPOIPCT (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61F 2/14 (2006.01) A61K 47/42 (2017.01) kind of national protection available): AE, AG, AL, AM, A61K 38/17 (2006.01) CO7K 14/435 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, (21) International Application Number: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, PCT/US2017/046659 DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, (22) International Filing Date: KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, 12 August 2017 (12.08.2017) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (25) Filing Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (26) Publication Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 62/374,532 12 August 2016 (12.08.2016) US kind of regional protection available): ARIPO (BW, GH, 62/407,863 13 October 2016 (13.10.2016) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, 62/467,697 06 March 2017 (06.03.2017) US UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (71) Applicant: SILK TECHNOLOGIES, LTD. [US/US]; EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, 3700 Annapolis Ln N, Ste 105, Plymouth, Minnesota 55447 MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (US). TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, (72) Inventors: LAWRENCE, Brian D.; 51 Sandpiper Road, KM, ML, MR, NE, SN, TD, TG). _ Tampa, Florida 33609 (US). INFANGER, David W.; 6236 = Troy Lane North, Maple Grove, Minnesota 55311 (US). Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) = (74) Agent: HAUKAAS, Michael H.; 5100 Eden Avenue, Suite _ 303, Edina, Minnesota 55436 (US). (54) Title: SILK-DERIVED PROTEIN FOR TREATING INFLAMMATION = 1 . 5 — A e.v '••••••4 •••4 ee4v e••••0 .••• 4 1.0 = c*:•:1 ... 4 :::::::: NAN% ,:o ' ::o .:.:4 ox *4 0:4 4 , , H202 SIGNAL X: M 1......„ I I • • • (FOLD CONTROL) 0:+:; :* 1 .*x M 4:o 0 t i m, *:* 0.•40 = 4...0 SW4 I 1 = g C + • :: e••••0 • :•N • •• •4 C.:4•4 1,••11 + :4 W9 ......v ow : • A k x.:4 . A 4444 M _ 1-1 '• M IN CT - - 1 4.) M © -- -- GC (57) : Described herein are methods for reducing proteins (SDP) or a fraction thereof to a subject having 0 conditions and wounds, including corneal wounds, comprising N described herein. ;;;$ an 0.5% P A S F inflammation inflammatory condition. the topical a Fig. by administration 1 . 0 % SDP 5 administration The methods a of 5.0% SDP-4 of an effective amount of silk-derived include the treatment of inflammatory an effective amount of SDP material as C [Continued on next page] WO 2018/031973 Al MIDEDIMOHNOBEIERIMIDEMEIERVON Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event amendments (Rule 48.2(h)) of receipt of
SG11201901137UA 2016-08-12 2017-08-12 Silk-derived protein for treating inflammation SG11201901137UA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662374532P 2016-08-12 2016-08-12
US201662407863P 2016-10-13 2016-10-13
US201762467697P 2017-03-06 2017-03-06
PCT/US2017/046659 WO2018031973A1 (en) 2016-08-12 2017-08-12 Silk-derived protein for treating inflammation

Publications (1)

Publication Number Publication Date
SG11201901137UA true SG11201901137UA (en) 2019-03-28

Family

ID=61163249

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201901137UA SG11201901137UA (en) 2016-08-12 2017-08-12 Silk-derived protein for treating inflammation

Country Status (11)

Country Link
US (2) US11242367B2 (en)
EP (1) EP3496662A4 (en)
JP (1) JP2019531334A (en)
KR (1) KR102275012B1 (en)
CN (1) CN109862851A (en)
AU (1) AU2017310520A1 (en)
CA (1) CA3033507A1 (en)
MX (1) MX2019001633A (en)
NZ (1) NZ751231A (en)
SG (1) SG11201901137UA (en)
WO (1) WO2018031973A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9394355B2 (en) 2014-08-20 2016-07-19 Silk Technologies, Ltd. Fibroin-derived protein composition
WO2019094702A1 (en) 2017-11-10 2019-05-16 Cocoon Biotech Inc. Ocular applications of silk-based products
EP3910096A4 (en) * 2019-01-09 2023-05-24 Spiber Inc. MODIFIED FIBROIN
WO2020247594A1 (en) 2019-06-04 2020-12-10 Cocoon Biotech Inc. Silk-based products, formulations, and methods of use
KR102374291B1 (en) * 2019-09-10 2022-03-14 강릉원주대학교산학협력단 Feed additive composition containing natural pozzolan
JP7670704B2 (en) * 2019-11-15 2025-04-30 シルク テクノロジーズ、リミテッド Stable formulation of silk-derived proteins
IT201900023142A1 (en) * 2019-12-05 2021-06-05 Sifi Spa OCULAR TOPICAL COMPOSITION CONTAINING METABOLITES OF LACTOBACILLUS FERMENTATION
KR102194995B1 (en) * 2020-09-16 2020-12-28 장혜란 stabilization compoation of improved dried humoral diagnosis and its opplication method
US12161693B2 (en) 2021-04-14 2024-12-10 Cocoon Biotech Inc. Methods of making stable silk fibroin formulations
JP2024538181A (en) * 2021-10-18 2024-10-18 エボルブド バイ ネイチャー， インコーポレイテッド Silk-stimulated collagen and claudin-1 expression and silk-stimulated anti-inflammatory effects
CN114685825B (en) * 2022-03-22 2023-02-28 浙江大学 A kind of preparation method of silk protein co-crystal gel and its product and application
CN117288958B (en) * 2023-09-18 2025-08-29 福州大学附属省立医院 Application of a protein detection reagent in the preparation of a product for diagnosing aggressive behavior in schizophrenia

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5931520B2 (en) 1979-03-22 1984-08-02 カネボウ株式会社 Method for producing silk fibroin peptide aqueous solution
IL101850A (en) 1991-06-13 1996-01-31 Janssen Pharmaceutica Nv 11-(4-Piperidinyl)-imidazo (2,1-b) (3) benzazepine derivatives their preparation and pharmaceutical compositions containing them
CA2125060C (en) 1993-07-02 1999-03-30 Henry P. Dabrowski Ophthalmic solution for artificial tears
JPH0767686A (en) 1993-09-06 1995-03-14 Shinano Kenshi Co Ltd Production of silk fibroin peptide having low molecular weight
US5760004A (en) 1994-11-21 1998-06-02 Protein Polymer Technologies, Inc. Chemical modification of repetitive polymers to enhance water solubility
JP3449658B2 (en) 1994-12-21 2003-09-22 杏林製薬株式会社 8-Alkoxyquinolonecarboxylic acid hydrate excellent in stability and method for producing the same
US5895645A (en) 1995-01-31 1999-04-20 Bausch & Lomb Incorporated Opthalmic solution for artificial tears
JPH08295697A (en) 1995-04-26 1996-11-12 Kanebo Ltd Production of aqueous solution of silk fibroin at high concentration
AU2022599A (en) 1997-12-31 1999-07-19 Kimberly-Clark Worldwide, Inc. Method of reducing molecular weights and polydispersity indices of polymers of ethylene oxide
FR2774588B1 (en) 1998-02-11 2000-05-05 Oreal COSMETIC OR DERMATOLOGICAL COMPOSITION CONTAINING AT LEAST ONE NATURAL, RECOMBINANT ARACHNID SILK PROTEIN OR THE LIKE
CN1133432C (en) 1998-08-21 2004-01-07 千寿制药株式会社 Aqueous liquid preparations
JP2000143472A (en) 1998-11-10 2000-05-23 Hiroshi Akai Cosmetic having ultraviolet light-absorbing function
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
NZ521185A (en) 2000-07-14 2005-02-25 Allergan Inc Compositions containing alpha-2-adrenergic agonist components
US8858961B2 (en) 2000-07-14 2014-10-14 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
KR20030023700A (en) 2000-07-14 2003-03-19 알러간, 인코포레이티드 Compositions containing therapeutically active components having enhanced solubility
US20030206897A1 (en) 2000-09-13 2003-11-06 The Procter & Gamble Company Cosmetic compositions
IT1316885B1 (en) 2000-10-02 2003-05-13 Consorzio Per Gli Studi Uni PROCEDURE FOR THE PREPARATION OF A NON-WOVEN FABRIC IN SILK FIBER.
CN1277584C (en) 2001-10-25 2006-10-04 康涅狄格大学 Biologically active substances, methods of preparing biologically active substances and methods of use thereof
WO2003045336A1 (en) 2001-11-29 2003-06-05 National Institute Of Agrobiological Sciences Emulsifier and process for producing the same
US7351404B2 (en) 2002-02-04 2008-04-01 Allergan, Inc. Method of enhancing hair growth
US7642258B2 (en) 2002-04-19 2010-01-05 Allergan, Inc. Combination of brimonidine and timolol for topical ophthalmic use
US7030149B2 (en) 2002-04-19 2006-04-18 Allergan, Inc. Combination of brimonidine timolol for topical ophthalmic use
US7842780B2 (en) 2003-01-07 2010-11-30 Trustees Of Tufts College Silk fibroin materials and use thereof
US7060260B2 (en) 2003-02-20 2006-06-13 E.I. Du Pont De Nemours And Company Water-soluble silk proteins in compositions for skin care, hair care or hair coloring
KR20040077553A (en) * 2003-02-28 2004-09-04 독립행정법인농업생물자원연구소 Extraction and utilization of cell growth promoting peptides from silk protein
US7115388B2 (en) 2003-03-14 2006-10-03 National Institute Of Agrobiological Sciences Production of functional polypeptides originating from silk protein and use thereof
US20050196370A1 (en) 2003-03-18 2005-09-08 Zhi-Jian Yu Stable ophthalmic oil-in-water emulsions with sodium hyaluronate for alleviating dry eye
CA2562415C (en) 2003-04-10 2015-10-27 Tufts University Concentrated aqueous silk fibroin solutions free of organic solvents and uses thereof
CA2468664C (en) 2003-06-03 2012-03-06 Allergan, Inc. Ketorolac tromethamine compositions for treating or preventing ocular pain
JP2007501799A (en) 2003-08-07 2007-02-01 アラーガン、インコーポレイテッド Composition for delivering a medicament into the eye and methods for its preparation and use
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
EP1682537B1 (en) 2003-11-05 2012-03-28 SARcode Bioscience Inc. Modulators of cellular adhesion
US20050202097A1 (en) 2004-03-12 2005-09-15 Melbj Holdings, Llc, Florida Lubricant for the ocular surface
EP1609801A1 (en) 2004-06-25 2005-12-28 Technische Universität München Proteins of natural origin and materials made therefrom
US10010574B2 (en) 2004-07-31 2018-07-03 Brainguard Co., Ltd. Silk peptide for improving neuroprotective and neurofunctional effects and a method of its preparation
US8569367B2 (en) 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
WO2010102078A1 (en) 2009-03-04 2010-09-10 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
US7851504B2 (en) 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
EP2444079B1 (en) 2005-05-17 2016-11-30 SARcode Bioscience Inc. Compositions and Methods for Treatment of Eye Disorders
JP5748392B2 (en) 2005-10-05 2015-07-15 コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガナイゼーション Silk protein
DK3150209T3 (en) 2006-03-31 2019-10-28 Vistakon Pharmaceuticals Llc Ocular allergy treatments
WO2007130364A2 (en) 2006-05-01 2007-11-15 Riolan Technologies, Inc. Compositions, methods, and kits for treating dry eye
WO2008109138A1 (en) 2007-03-07 2008-09-12 Grune Guerry L Spf compositions
CN104013598A (en) 2007-05-29 2014-09-03 塔夫茨大学信托人 Method for silk fibroin gelation using sonication
CN101194666A (en) 2007-11-28 2008-06-11 吴江市方霞企业信息咨询有限公司 Silkworm chrysalis fibroin protein functional food
WO2009088119A1 (en) 2008-01-07 2009-07-16 Bioleaders Corporation Composition for preventing or treating dry eye syndrome comprising poly-gamma-glutamic acid
US7842714B2 (en) 2008-03-03 2010-11-30 Allergan, Inc. Ketorolac tromethamine compositions for treating ocular pain
WO2009139817A2 (en) 2008-04-15 2009-11-19 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
US8569730B2 (en) 2008-07-08 2013-10-29 Sandisk 3D Llc Carbon-based interface layer for a memory device and methods of forming the same
WO2010141133A2 (en) 2009-03-04 2010-12-09 Trustees Of Tufts College Silk fibroin systems for antibiotic delivery
US20110014287A1 (en) 2009-04-20 2011-01-20 Altman Gregory H Silk Fibroin Hydrogels and Uses Thereof
MX358504B (en) 2009-06-05 2018-08-21 Allergan Inc ARTIFICIAL TEARS and THERAPEUTIC USES.
IN2012DN00445A (en) 2009-07-14 2015-05-15 Tufts College
WO2011050175A1 (en) 2009-10-21 2011-04-28 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
WO2011109691A2 (en) 2010-03-05 2011-09-09 Trustees Of Tufts College Silk-based ionomeric compositions
US8309689B2 (en) 2010-05-20 2012-11-13 Taipei Medical University High yield dialysis-free process for producing organosoluble regenerated silk fibroin
CA2839719A1 (en) 2010-06-17 2011-12-22 Tufts University / Trustees Of Tufts College Silk optical particles and uses thereof
US20140193466A1 (en) 2011-06-07 2014-07-10 Cornell University Silk compositions and methods of using same
CN102860969A (en) 2011-07-07 2013-01-09 刘畅 Soybean eye cream
JP2015508104A (en) 2012-02-22 2015-03-16 トラスティーズ オブ タフツ カレッジ Compositions and methods for the delivery of therapeutic agents to the eye
US9056063B2 (en) 2012-03-13 2015-06-16 James E. Hanson Natural sunscreen composition
US20150079012A1 (en) 2012-04-20 2015-03-19 Trustees Of Tufts College Silk fibroin-based personal care compositions
SI3715345T1 (en) 2012-07-25 2024-07-31 Bausch + Lomb Ireland Limited PREPARATION OF THE LFA-1 INHIBITOR
WO2014127007A1 (en) 2013-02-12 2014-08-21 Seryx Biomedical, Inc. Ophthalmic formulation derived from silk protein
MX367597B (en) 2013-03-15 2019-08-28 Patheon Softgels Inc Silk-based capsules.
EP3412682B1 (en) 2013-03-15 2022-08-31 Trustees Of Tufts College Low molecular weight silk compositions and stabilizing silk compositions
CN103239707A (en) 2013-05-22 2013-08-14 江苏紫石化工科技有限公司 Eye drop for treating myopia
EP4509520A3 (en) 2013-09-30 2025-10-22 Evolved by Nature, Inc. Silk protein fragment compositions and articles manufactured therefrom
AU2014353110B2 (en) 2013-11-19 2018-05-10 Cornell University Tissue scaffold materials for tissue regeneration and methods of making
US9394355B2 (en) * 2014-08-20 2016-07-19 Silk Technologies, Ltd. Fibroin-derived protein composition
US10758645B2 (en) * 2014-12-17 2020-09-01 Tufts University Injectable, flexible hydroxyapatite-silk foams for osteochondral and dental repair
CA3020342A1 (en) * 2016-04-08 2017-11-23 Cornell University A method to enhance wound healing using silk-derived protein

Also Published As

Publication number Publication date
KR20190042608A (en) 2019-04-24
JP2019531334A (en) 2019-10-31
EP3496662A1 (en) 2019-06-19
US11242367B2 (en) 2022-02-08
MX2019001633A (en) 2019-09-18
NZ751231A (en) 2025-08-29
CN109862851A (en) 2019-06-07
CA3033507A1 (en) 2018-02-15
AU2017310520A1 (en) 2019-03-21
WO2018031973A1 (en) 2018-02-15
EP3496662A4 (en) 2019-10-30
US20190169243A1 (en) 2019-06-06
KR102275012B1 (en) 2021-07-07
US20220332773A1 (en) 2022-10-20

Similar Documents

Publication Publication Date Title
SG11201901137UA (en) Silk-derived protein for treating inflammation
SG11201908790PA (en) Glucocorticoid receptor modulators to treat cervical cancer
SG11201906297QA (en) Nucleic acids encoding crispr-associated proteins and uses thereof
SG11201906431UA (en) Method for the treatment of thromboembolism
SG11201907034PA (en) Methods of treating influenza
SG11201909383PA (en) Customizable composite dressings for improved granulation and reduced maceration negative-pressure treatment
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201909960UA (en) Methods for improving memory and cognition and for treating memory and cognitive disorders
SG11201900809TA (en) Combination steerable catheter and systems
SG11201808693WA (en) Anti-il-33 antibodies, compositions, methods and uses thereof
SG11201806322QA (en) Maytansinoid derivatives, conjugates thereof, and methods of use
SG11201811019TA (en) Device for cardiac valve repair and method of implanting the same
SG11201807784SA (en) 3-desoxy derivative and pharmaceutical compositions thereof
SG11201810034XA (en) ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
SG11201805828YA (en) Method of treating c3 glomerulopathy
SG11201804814YA (en) Materials and methods for delivering nucleic acids to cochlear and vestibular cells
SG11201908326YA (en) Methods of treating neurodegenerative diseases
SG11201909155VA (en) Ask1 inhibitor compounds and uses thereof
SG11201408153YA (en) Prostate-specific membrane antigen antibody drug conjugates
SG11201809908TA (en) Stabilized glycopeptide antibiotic formulations
SG11201808804TA (en) A method to enhance wound healing using silk-derived protein
SG11201803834UA (en) Methods for treating conditions associated with masp-2 dependent complement activation
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201408240TA (en) Treatment of motor and movement disorder side effects associated with parkinson's disease treatments
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same